Ambit Biosciences Corp Company Profile (NASDAQ:AMBI)

About Ambit Biosciences Corp (NASDAQ:AMBI)

Ambit Biosciences Corp logoAmbit Biosciences Corporation is a biopharmaceutical company. The Company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. The Company's lead drug candidate, quizartinib, is in Phase IIb clinical development in patients with relapsed/refractory acute myeloid leukemia (AML). The Company's second drug candidate in clinical development, AC410, is a potent, selective, orally-administered, small molecule inhibitor of Janus kinase 2 (JAK2) that has potential utility for the treatment of autoimmune and inflammatory diseases. The Company's third program consists of two selective small molecule compounds, AC708 and AC855, which inhibit the colony-stimulating factor-1 receptor (CSF1R), a receptor tyrosine kinase.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: NASDAQ:AMBI
  • CUSIP: N/A
  • Web: N/A
Average Prices:
  • 50 Day Moving Avg: $40.00
  • 200 Day Moving Avg: $36.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.50
  • P/E Growth: 0
  • Dividend Yield: 1.0%

Frequently Asked Questions for Ambit Biosciences Corp (NASDAQ:AMBI)

What is Ambit Biosciences Corp's stock symbol?

Ambit Biosciences Corp trades on the NASDAQ under the ticker symbol "AMBI."

How were Ambit Biosciences Corp's earnings last quarter?

Ambit Biosciences Corp (NASDAQ:AMBI) issued its earnings results on Tuesday, May, 6th. The company reported ($0.50) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.47) by $0.03. The company had revenue of $0.03 million for the quarter, compared to analysts' expectations of $3.50 million. View Ambit Biosciences Corp's Earnings History.

Who are some of Ambit Biosciences Corp's key competitors?

How do I buy Ambit Biosciences Corp stock?

Shares of Ambit Biosciences Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ambit Biosciences Corp's stock price today?

One share of Ambit Biosciences Corp stock can currently be purchased for approximately $15.60.

MarketBeat Community Rating for Ambit Biosciences Corp (NASDAQ AMBI)
Community Ranking:  3.4 out of 5 (  )
Outperform Votes:  28 (Vote Outperform)
Underperform Votes:  13 (Vote Underperform)
Total Votes:  41
MarketBeat's community ratings are surveys of what our community members think about Ambit Biosciences Corp and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Ambit Biosciences Corp (NASDAQ:AMBI) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Ambit Biosciences Corp (NASDAQ:AMBI)
No equities research coverage for this company has been tracked by


Earnings History for Ambit Biosciences Corp (NASDAQ:AMBI)
Earnings by Quarter for Ambit Biosciences Corp (NASDAQ:AMBI)
Earnings History by Quarter for Ambit Biosciences Corp (NASDAQ AMBI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/12/2014Q2 2014($0.58)($0.68)$0.03 million$0.03 millionViewListenView Earnings Details
5/6/2014Q1($0.47)($0.50)$3.50 million$0.03 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Ambit Biosciences Corp (NASDAQ:AMBI)
Current Year EPS Consensus Estimate: $-1.99 EPS
Next Year EPS Consensus Estimate: $-2.08 EPS


Dividend History for Ambit Biosciences Corp (NASDAQ:AMBI)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Ambit Biosciences Corp (NASDAQ:AMBI)
Insider Trades by Quarter for Ambit Biosciences Corp (NASDAQ:AMBI)
Insider Trades by Quarter for Ambit Biosciences Corp (NASDAQ:AMBI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/24/2013Foresite Capital Management I,major shareholderBuy79,569$6.93$551,413.17View SEC Filing  
5/23/2013Orbimed Advisors LlcMajor ShareholderBuy33,800$6.91$233,558.00View SEC Filing  
5/21/2013David P BonitaDirectorBuy680,471$7.97$5,423,353.87View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Ambit Biosciences Corp (NASDAQ:AMBI)
Latest Headlines for Ambit Biosciences Corp (NASDAQ:AMBI)



Ambit Biosciences Corp (AMBI) Chart for Friday, July, 21, 2017

This page was last updated on 7/21/2017 by Staff